Quantitative Concept – Page 8

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

3 months ago talkbio0Tagged Approved, Ataxia, Spinocerebellar, Capital, Investments, non-dilutive, Note (document), secured, United States Food and Drug Administration

Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

3 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Pfizer’s Sasanlimab Shows 32% Reduction in Bladder Cancer Risk But Misses Secondary Endpoints in Phase 3 CREST Trial

3 months ago talkbio0Tagged BCG Vaccine, Event-Free Survival, Inhibitor, Invasive, Malignant neoplasm of urinary bladder, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Overall Survival, PDCD1 gene, Phase 3 CREST trial, Sasanlimab, subcutaneous administration

Sasanlimab (PD-1 inhibitor), Bladder cancer risk reduction, Phase 3 CREST trial, BCG combination therapy, Non-muscle invasive bladder cancer (NMIBC), Event-free survival (EFS), Overall survival (OS) endpoint missed, Subcutaneous administration

Mercks Gardasil sales sink further amid China market pressure

3 months ago talkbio0Tagged China, Gardasil, Gardasil sales, Growth, Market, Pressure- physical agent

Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China

Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge

3 months ago talkbio0Tagged Altuviiio, Dupixent, Sales - occupational activity, sanofi, United States Food and Drug Administration

Altuviiio, Sales – occupational activity, sanofi, Dupixent, United States Food and Drug Administration

Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations

3 months ago talkbio0Tagged CEOs, EU, Financial cost, Investments, Market, nations, Novartis, Parity, Pharma, Prices, sanofi, Transplant Registry Unified Management Program, U.S.

EU, Novartis, CEOs, Transplant Registry Unified Management Program, Financial cost, Parity, sanofi, Investments, Prices, Pharma, Market, nations, U.S.